CPhGs dose-dependently alleviated the degree of liver fibrosis and inhibited HSC transformation into myofibroblast-like cells, reduced the elevated levels of serum ALT, AST, HA, LN, CIV, TGF-β1 and the liver index, and markedly suppressed expression of collagen I, collagen III and TGF-β1 in liver tissue. This evidence concerns the gene TGFB1 and Hepatic fibrosis.